Search Results | Clinical Cancer Research | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma

Koos Koole, Diede Brunen, Pauline M.W. van Kempen, Rob Noorlag, Remco de Bree, Cor Lieftink, Robert J.J. van Es, René Bernards, Stefan M. Willems

Clin Cancer Res (2016) 22 (15): 3884–3893.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-1874

Published: 31 July 2016

View article

Includes: Supplementary data

Journal Articles

Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer

Geert O. Janssens, Saskia E. Rademakers, Chris H. Terhaard, Patricia A. Doornaert, Hendrik P. Bijl, Piet van den Ende, Alim Chin, Robert P. Takes, Remco de Bree, Ilse J. Hoogsteen, Johan Bussink, Paul N. Span, Johannes H. Kaanders

Clin Cancer Res (2014) 20 (5): 1345–1354.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-1730

Published: 02 March 2014

View article

Includes: Supplementary data

Journal Articles

Phase I Therapy Study with ¹⁸⁶Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma

Pontus K. E. Börjesson, Ernst J. Postema, Jan C. Roos, David R. Colnot, Henri A. M. Marres, Mathijs H. van Schie, Gerd Stehle, Remco de Bree, Gordon B. Snow, Wim J. G. Oyen, Guus A. M. S. van Dongen

Clin Cancer Res (2003) 9 (10): 3961s–3972s.

Published: 31 August 2009

View article

Journal Articles

A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus

Bernard M. Tijink, Jan Buter, Remco de Bree, Giuseppe Giaccone, Margreet S. Lang, Alexander Staab, C. René Leemans, Guus A.M.S. van Dongen

Clin Cancer Res (2006) 12 (20): 6064–6072.

DOI: https://doi.org/10.1158/1078-0432.CCR-06-0910

Published: 24 October 2006

View article

Journal Articles

Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients

Pontus K.E. Börjesson, Yvonne W.S. Jauw, Ronald Boellaard, Remco de Bree, Emile F.I. Comans, Jan C. Roos, Jonas A. Castelijns, Maria J.W.D. Vosjan, J. Alain Kummer, C. René Leemans, Adriaan A. Lammertsma, Guus A.M.S. van Dongen

Clin Cancer Res (2006) 12 (7): 2133–2140.

DOI: https://doi.org/10.1158/1078-0432.CCR-05-2137

Published: 11 April 2006

View article

Journal Articles

Reinfusion of Unprocessed, Granulocyte Colony-stimulating Factor-stimulated Whole Blood Allows Dose Escalation of ¹⁸⁶Relabeled Chimeric Monoclonal Antibody U36 Radioimmunotherapy in a Phase I Dose Escalation Study

David R. Colnot, Gert J. Ossenkoppele, Jan C. Roos, Jasper J. Quak, Remco de Bree, Pontus K. Börjesson, Peter C. Huijgens, Gordon B. Snow, Guus A. M. S. van Dongen

Clin Cancer Res (2002) 8 (11): 3401–3406.

Published: 01 November 2002

View article

Journal Articles

Sensitive Detection of Squamous Cells in Bone Marrow and Blood of Head and Neck Cancer Patients by E48 Reverse Transcriptase-Polymerase Chain Reaction

Ruud H. Brakenhoff, Joep G. W. Stroomer, Corlinda ten Brink, Remco de Bree, Sjerp M. Weima, Gordon B. Snow, Guus A. M. S. van Dongen

Clin Cancer Res (1999) 5 (4): 725–732.

Published: 01 April 1999

View article

NARROW

FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma

Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer

Phase I Therapy Study with ¹⁸⁶Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma

A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus

Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients

Reinfusion of Unprocessed, Granulocyte Colony-stimulating Factor-stimulated Whole Blood Allows Dose Escalation of ¹⁸⁶Relabeled Chimeric Monoclonal Antibody U36 Radioimmunotherapy in a Phase I Dose Escalation Study

Sensitive Detection of Squamous Cells in Bone Marrow and Blood of Head and Neck Cancer Patients by E48 Reverse Transcriptase-Polymerase Chain Reaction

Email alerts

AACR Journals

FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma

Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer

Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma

A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus

Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients

Reinfusion of Unprocessed, Granulocyte Colony-stimulating Factor-stimulated Whole Blood Allows Dose Escalation of 186Relabeled Chimeric Monoclonal Antibody U36 Radioimmunotherapy in a Phase I Dose Escalation Study

Sensitive Detection of Squamous Cells in Bone Marrow and Blood of Head and Neck Cancer Patients by E48 Reverse Transcriptase-Polymerase Chain Reaction

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Phase I Therapy Study with ¹⁸⁶Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma

Reinfusion of Unprocessed, Granulocyte Colony-stimulating Factor-stimulated Whole Blood Allows Dose Escalation of ¹⁸⁶Relabeled Chimeric Monoclonal Antibody U36 Radioimmunotherapy in a Phase I Dose Escalation Study